Form 8-K - Current report:
SEC Accession No. 0001437749-25-023048
Filing Date
2025-07-21
Accepted
2025-07-21 08:01:11
Documents
17
Period of Report
2025-07-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dmtp20250720_8k.htm   iXBRL 8-K 36309
2 EXHIBIT 10.1 ex_840933.htm EX-10.1 254108
3 EXHIBIT 10.2 ex_840934.htm EX-10.2 94221
4 EXHIBIT 99.1 ex_840932.htm EX-99.1 16834
9 diamedicalogo.jpg GRAPHIC 6910
  Complete submission text file 0001437749-25-023048.txt   629250

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA dmac-20250721.xsd EX-101.SCH 3580
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dmac-20250721_def.xml EX-101.DEF 11413
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE dmac-20250721_lab.xml EX-101.LAB 15291
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dmac-20250721_pre.xml EX-101.PRE 11573
20 EXTRACTED XBRL INSTANCE DOCUMENT dmtp20250720_8k_htm.xml XML 2842
Mailing Address 301 CARLSON PARKWAY SUITE 210 MINNEAPOLIS MN 55305
Business Address 301 CARLSON PARKWAY SUITE 210 MINNEAPOLIS MN 55305 (763) 496-5454
DiaMedica Therapeutics Inc. (Filer) CIK: 0001401040 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36291 | Film No.: 251135745
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)